DSIP (Delta Sleep-Inducing Peptide)

Also referred to as Delta sleep-inducing peptide, DSIP peptide.

Status: Investigational. DSIP is not an FDA-approved drug product in the United States and has no established clinical indication anywhere. Its name comes from a 1970s study in rabbits in which the peptide was isolated from blood associated with delta-wave sleep activity, and that name has since led many readers to assume a demonstrated sleep benefit in people that the human literature does not actually support. Decades of subsequent research have produced inconsistent and largely small human findings, and no regulatory body has approved DSIP for sleep or any other use.

Delta sleep-inducing peptide, or DSIP, is a short peptide first isolated from the blood of rabbits in the 1970s during studies of sleep induction, a discovery that gave it a name suggesting a sleep-promoting function it has not been shown to reliably reproduce in humans. It is not an FDA-approved drug product, and despite decades of subsequent research, the human sleep evidence is inconsistent and largely limited to small, older studies. Patients often ask about DSIP assuming its name reflects an established mechanism, when in fact the name reflects a single historical animal observation. Understanding that history is essential to interpreting any claim made about this peptide today.

What it is

DSIP is a short, nine-amino-acid peptide first identified in the blood of rabbits during electroencephalographic studies of sleep in the 1970s. Its exact endogenous role in humans, including whether it circulates naturally as a discrete signalling molecule at physiologically meaningful levels, is not settled science. It exists today only as a synthesized research peptide, not as an approved or naturally sourced pharmaceutical product.

Why people ask about it

Patients raise DSIP almost entirely because of its name, which sounds like a direct description of a proven sleep mechanism. Many are seeking alternatives to prescription sleep aids and find DSIP discussed in online communities as a "natural" or peptide-based option. The name itself, more than any specific piece of evidence, is usually what drives the question.

Proposed mechanism

The proposed mechanism is drawn from older animal electrophysiology work and has not been clearly established in humans. Early rabbit studies proposed that DSIP directly promotes delta-wave (slow-wave) sleep activity, the basis for its name, but later human studies have not consistently reproduced a clear, dose-related increase in delta-wave sleep. Other proposed, largely unconfirmed roles include effects on stress-hormone regulation and circadian signalling, described mainly in older and smaller studies rather than in a coherent modern mechanistic picture.

What researchers have studied

• Original 1970s rabbit studies isolating and characterizing DSIP from blood
• Older human studies examining EEG sleep-stage changes after administration
• Studies of DSIP's relationship to stress-hormone (cortisol/ACTH axis) regulation
• Investigations into whether DSIP functions as a true circulating signalling peptide in humans
• Comparative studies attempting, with mixed results, to reproduce the original animal sleep findings

Human evidence

• Human studies are old, small, and inconsistent in design, several dating from decades ago with methodology that would not meet current trial standards.
• Findings on whether DSIP reliably increases delta-wave (slow-wave) sleep in humans are mixed, with some studies reporting no clear effect.
• No modern, adequately powered, placebo-controlled human trial establishing a sleep benefit was identified in the accessible literature.
• The gap between the peptide's name and what has actually been demonstrated in humans is a recurring point of confusion in secondary sources discussing DSIP.

Preclinical evidence

• The original 1970s studies isolated DSIP from rabbit blood in the context of delta-wave sleep activity.
• Subsequent animal studies examined effects on stress-hormone regulation.
• Some animal work explored circadian rhythm-related signalling.
• Later animal replication attempts of the original sleep findings have produced inconsistent results.

What is not yet known

• Whether DSIP has any reliable, reproducible effect on human sleep architecture under modern trial conditions.
• Whether DSIP functions as a genuine, physiologically relevant circulating peptide in humans at all.
• Long-term safety of repeated use.
• Any dose-response or timing relationship applicable to a general population, given the absence of established clinical use.
• How synthesized research-grade DSIP compares to whatever the original 1970s rabbit-derived material actually was.
• Interaction risk with sedatives, sleep medications, or other centrally acting drugs.

Regulatory status and access

Where DSIP has been prepared by a compounding pharmacy on a physician's order, that preparation is not FDA-approved and its quality is not certified by the compounding process itself. Current permissibility of compounding DSIP must be verified independently and is subject to change. Ask about current availability. A physician determines whether further discussion is appropriate only after an individual evaluation.

Known and potential risks

• The evidence gap between DSIP's suggestive name and its actual demonstrated effects in humans creates a meaningful risk of overestimating benefit.
• US supply is unregulated by the FDA, so identity, purity, and sterility of research-chemical or compounded material cannot be assumed.
• Long-term human safety data is essentially absent given how limited and old the existing studies are.
• Self-directed use for sleep concerns may delay evaluation and treatment of an underlying sleep disorder.
• Unknown interaction risk with prescription sleep aids, sedatives, or other centrally acting medications.

Cautions and who may not be a candidate

• Pregnancy and breastfeeding, where no safety data exist.
• Undiagnosed sleep disorders (such as sleep apnea) that require direct clinical evaluation rather than self-directed peptide use.
• Concurrent use of prescription sedative-hypnotics or other centrally acting sleep medications without physician coordination.
• Adrenal or pituitary axis disorders, given DSIP's studied relationship to stress-hormone regulation.
• Reliance on DSIP in place of evaluation for a persistent or worsening sleep complaint.

Questions to discuss with a physician

• What does the actual human evidence show, separate from what the name DSIP implies?
• Could an underlying sleep disorder explain my symptoms better than anything a peptide would address?
• What is the current legal and compounding status of DSIP in the US?
• Are there FDA-approved sleep treatments that should be considered first?
• What interaction risk exists with medications or supplements I already use?
• How would we assess whether this was providing any real effect versus a placebo response?

Frequently asked questions

Is DSIP FDA-approved?

No. DSIP is not an FDA-approved drug product for sleep or any other use, and it has no established clinical indication.

Does GOAL.MD sell DSIP?

This page is educational and is not an offer to sell or ship DSIP. Ask about current availability, and appropriateness is determined only by a physician after individual evaluation.

Where does the name delta sleep-inducing peptide come from?

It comes from a 1970s study that isolated the peptide from the blood of rabbits during research on delta-wave sleep activity. The name reflects that single historical animal observation, not a demonstrated human mechanism.

Does DSIP actually induce delta-wave sleep in humans?

The human evidence is old, small, and inconsistent, with some studies reporting no clear effect on delta-wave sleep. A reliable, reproducible human effect has not been established.

Is DSIP a natural hormone the body already makes?

Whether DSIP circulates naturally in humans as a meaningful, discrete signalling molecule is not settled science. It should not be assumed to be an established natural hormone with a defined physiological role.

Can DSIP treat insomnia?

It is not an approved treatment for insomnia or any other sleep disorder, and the available evidence does not support that claim. Persistent sleep problems warrant direct clinical evaluation.

Why do online sources describe DSIP so confidently as a sleep aid?

This largely traces back to the peptide's name and secondary online summaries repeating it, rather than to a strong, current body of human clinical evidence.

Is DSIP safe?

Long-term human safety data is essentially absent given how old and limited the existing studies are, and unregulated supply adds additional identity and purity risk. This should be discussed directly with a physician.

How is DSIP different from Semax or Selank?

DSIP's research history centers on a single 1970s animal sleep observation with inconsistent human follow-up, whereas Semax and Selank have more developed, though still limited, Russian human research programs behind their respective registrations.

Who should avoid discussing DSIP?

Anyone who is pregnant or breastfeeding, has an undiagnosed sleep disorder, has an adrenal or pituitary condition, or is currently on a prescription sedative should raise these specifics with a physician before any such discussion.

What is DSIP (Delta Sleep-Inducing Peptide)?

DSIP is a short, nine-amino-acid peptide first identified in the blood of rabbits during electroencephalographic studies of sleep in the 1970s. Its exact endogenous role in humans, including whether it circulates naturally as a discrete signalling molecule at physiologically meaningful levels, is not settled science. It exists today only as a synthesized research peptide, not as an approved or naturally sourced pharmaceutical product.

Is DSIP (Delta Sleep-Inducing Peptide) FDA-approved?

DSIP is not an FDA-approved drug product in the United States and has no established clinical indication anywhere. Approval status describes regulation, not effectiveness.

Does the legal or regulatory status of DSIP (Delta Sleep-Inducing Peptide) tell me whether it works?

No. Regulatory status describes what may lawfully be made, prescribed, or sold, and it is a separate question from what the research shows. On this page the regulatory description and the evidence tiers are kept apart so neither is mistaken for the other.

Can a licensed U.S. compounding pharmacy prepare DSIP (Delta Sleep-Inducing Peptide)?

Where DSIP has been prepared by a compounding pharmacy on a physician's order, that preparation is not FDA-approved and its quality is not certified by the compounding process itself. Current permissibility of compounding DSIP must be verified independently and is subject to change.

What human evidence exists for DSIP (Delta Sleep-Inducing Peptide)?

Human information is limited to case reports or uncontrolled observations, which cannot establish benefit. Human studies are old, small, and inconsistent in design, several dating from decades ago with methodology that would not meet current trial standards.

Have there been controlled human trials of DSIP (Delta Sleep-Inducing Peptide)?

Published human information is limited to case-level or uncontrolled observation rather than controlled trials, so benefit has not been established.

What do case reports about DSIP (Delta Sleep-Inducing Peptide) actually show?

Case-level reports describe what happened to specific people without a comparison group. They can raise a question worth studying, and they cannot show that an effect was caused by the substance. Findings on whether DSIP reliably increases delta-wave (slow-wave) sleep in humans are mixed, with some studies reporting no clear effect.

What have animal and laboratory studies of DSIP (Delta Sleep-Inducing Peptide) reported?

The original 1970s studies isolated DSIP from rabbit blood in the context of delta-wave sleep activity; Subsequent animal studies examined effects on stress-hormone regulation; Some animal work explored circadian rhythm-related signalling. These are animal, tissue, or cell-culture findings. They describe a model, not a demonstrated result in people.

Do the animal findings for DSIP (Delta Sleep-Inducing Peptide) mean it works in people?

No. Findings in animals or in cell culture routinely fail to reproduce in humans, and a positive laboratory model is not evidence of a human benefit. Whether any of this translates to people is exactly what has not been established.

How is DSIP (Delta Sleep-Inducing Peptide) proposed to work?

The proposed mechanism is drawn from older animal electrophysiology work and has not been clearly established in humans. Early rabbit studies proposed that DSIP directly promotes delta-wave (slow-wave) sleep activity, the basis for its name, but later human studies have not consistently reproduced a clear, dose-related increase in delta-wave sleep. This is a proposed pathway rather than a demonstrated effect.

What is DSIP (Delta Sleep-Inducing Peptide) being studied for?

Published work has focused on Original 1970s rabbit studies isolating and characterizing DSIP from blood; Older human studies examining EEG sleep-stage changes after administration; Studies of DSIP's relationship to stress-hormone (cortisol/ACTH axis) regulation; Investigations into whether DSIP functions as a true circulating signalling peptide in humans. A research focus describes where questions are being asked, not where answers have been found.

What is still unknown about DSIP (Delta Sleep-Inducing Peptide)?

Whether DSIP has any reliable, reproducible effect on human sleep architecture under modern trial conditions; Whether DSIP functions as a genuine, physiologically relevant circulating peptide in humans at all; Long-term safety of repeated use; Any dose-response or timing relationship applicable to a general population, given the absence of established clinical use.

What are the risks of DSIP (Delta Sleep-Inducing Peptide)?

The evidence gap between DSIP's suggestive name and its actual demonstrated effects in humans creates a meaningful risk of overestimating benefit; US supply is unregulated by the FDA, so identity, purity, and sterility of research-chemical or compounded material cannot be assumed; Long-term human safety data is essentially absent given how limited and old the existing studies are.

Who should not consider DSIP (Delta Sleep-Inducing Peptide)?

A physician would generally consider it inappropriate in these situations without specialist input: Pregnancy and breastfeeding, where no safety data exist; Undiagnosed sleep disorders (such as sleep apnea) that require direct clinical evaluation rather than self-directed peptide use; Concurrent use of prescription sedative-hypnotics or other centrally acting sleep medications without physician coordination; Adrenal or pituitary axis disorders, given DSIP's studied relationship to stress-hormone regulation.

Is DSIP (Delta Sleep-Inducing Peptide) appropriate during pregnancy or breastfeeding?

No. Pregnancy and breastfeeding are listed as situations where this is not appropriate, because the safety data needed to make that judgement in those populations does not exist.

How does DSIP (Delta Sleep-Inducing Peptide) interact with other medications?

Interaction behaviour in people is not characterised for this substance, which is itself a reason a physician reviews the full medication list before any discussion. Unknown interaction risk with prescription sleep aids, sedatives, or other centrally acting medications.

What would a physician monitor if DSIP (Delta Sleep-Inducing Peptide) were discussed?

Monitoring concepts include Baseline sleep history and, where appropriate, objective sleep evaluation before any further discussion; Review of current sedative, hypnotic, or other centrally acting medications; Discussion of realistic expectations given the limited and old human evidence base. These are concepts a clinician would apply, not instructions for self-directed use.

Are products sold online as DSIP (Delta Sleep-Inducing Peptide) verified?

No. US supply is unregulated by the FDA, so identity, purity, and sterility of research-chemical or compounded material cannot be assumed. Material bought outside a licensed pharmacy has no verified identity, purity, or sterility.

How would a GOAL.MD physician evaluate a question about DSIP (Delta Sleep-Inducing Peptide)?

A physician starts with the problem you are trying to solve, reviews your history and current medications, and says plainly where the evidence stands. Medical appropriateness is determined only after a full evaluation, and for many substances the honest answer is that the evidence does not support use.

What should I ask a physician about DSIP (Delta Sleep-Inducing Peptide)?

Useful questions include: What does the actual human evidence show, separate from what the name DSIP implies?; Could an underlying sleep disorder explain my symptoms better than anything a peptide would address?; What is the current legal and compounding status of DSIP in the US?; Are there FDA-approved sleep treatments that should be considered first?.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.